Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary VLPs and manufacturing technologies. Medicago is developing VLP vaccines to protect against influenza, using a transient expression system producing recombinant antigens in non-transgenic plants. This technology has potential to offer speed and cost advantages over competitive technologies. It could allow vaccination of the population before the first wave of a pandemic strikes while supplying large volumes of vaccine antigens to the world market. The company also capitalizes on the high immunogenic potential of VLPs by developing a platform for the high-throughput discovery of new vaccine antigens.